Is Agios Pharmaceuticals (AGIO) Undervalued Following Stronger Q3 Results And Its FDA Review Update?

Agios Pharmaceuticals (AGIO) recently provided a third-quarter earnings update and news on its mitapivat regulatory review, showing a mixed performance with a 16.85% year-to-date gain but a 25.34% one-year decline. Analysts on Simply Wall St suggest the stock is 31% undervalued, with a fair value of $46.00 against a $31.76 close, primarily due to expectations for mitapivat's growth and pipeline assets. However, a high P/S ratio of 13.5x compared to an industry average of 10.3x indicates potential valuation risk if market sentiment shifts.